Treating Pregnant Women With Bipolar 1 Disorder Discussion

Treating Pregnant Women With Bipolar 1 Disorder Discussion

1. Recommend one FDA-approved drug, one off-label drug, and one nonpharmacological intervention for treating pregnant women with bipolar 1 disorder.
2. Explain the risk assessment you would use to inform your treatment decision-making. What are the risks and benefits of the FDA-approved medicine? What are the risks and benefits of the off-label drug?
3. Explain whether clinical practice guidelines exist for this disorder, and if so, use them to justify your recommendations. If not, explain what information you would need to take into consideration.
4. Support your reasoning with at least three current, credible scholarly resources, one each on the FDA-approved drug, the off-label, and a nonpharmacological intervention for the disorder Treating Pregnant Women With Bipolar 1 Disorder Discussion.

ORDER A PLAGIARISM-FREE PAPER HERE

One FDA-Approved Drug, One Off-Label Drug, and One Non-Pharmacological Intervention for Treating Pregnant Women with Bipolar 1 Disorder

Treatment of a pregnant woman with bipolar 1 disorder requires considerations for safety and the efficacy of drugs used. This is because of the teratogenicity effects of these drugs. Lamotrigine is an FDA-approved drug mood stabilizer and anticonvulsant for bipolar 1 disorder treatment. It effectively reduces depressive episodes that are difficult to manage during pregnancy. However, its use during the first trimester increases the risk of cleft palate and lip. It also requires blood level monitoring because its metabolism is altered by pregnancy (Dolk et al., 2016)Treating Pregnant Women With Bipolar 1 Disorder Discussion. It is pregnancy category C, where its benefits in depressive relapse prevention and mood stabilizing outweigh the disadvantages.

Quetiapine is used as an off-label drug in the treatment of bipolar disorder in pregnancy. It is an atypical antipsychotic drug that manages depressive symptoms and manic episodes. However, it has some risks that include weight gain and gestational diabetes (Reutfors et al., 2020)Treating Pregnant Women With Bipolar 1 Disorder Discussion. When used during the third trimester, there are increased risks of neonate withdrawal symptoms and extrapyramidal symptoms; it is pregnancy category C.

A non-pharmacological intervention, Cognitive behavioral therapy (CBT) is effective in bipolar 1 disorder management. CBT helps the client identify and change negative behaviors and thoughts; they come up with coping strategies and improved emotional control (Özdel et al., 2021)Treating Pregnant Women With Bipolar 1 Disorder Discussion. It is essential during pregnancy because it minimizes medication use, thus not predisposing the fetus to potential risks from medications. Together with pharmacotherapy, they form a critical part of the comprehensive treatment plan to ensure the improvement of symptoms.

The Risk Assessment Used to Inform Your Treatment Decision-Making, The Risks and Benefits of The FDA-Approved Medicine, and The Risks and Benefits of the Off-Label Drug

Risk assessment is essential to ensure the balance between the safety of the fetus and the mental health needs of the mother. Teratogenicity is a risk assessment to consider. This is the potentiality of a drug to lead to congenital malformations. During drug prescriptions to pregnant women, the gestation period is an important consideration. The first trimester is the critical one because of the organogenesis stages taking place. High teratogenic risk drugs are avoided in this period. Also, the mental health of the mother should be considered. This is because untreated bipolar disorder is characterized by mania episodes and severe depression that could result in suicide, self-harm, and reduced self-care. Breastfeeding considerations are important because some medications may affect the newborn when they pass into breast milk. It is, therefore, important to ensure medication safety postpartum during breastfeeding Treating Pregnant Women With Bipolar 1 Disorder Discussion.

The benefit of using lamotrigine is its effectiveness in reducing the severity and frequency of depressive episodes. Compared to other mood stabilizers like lithium, it has low teratogenic risks and is thus safe during pregnancy. This relapse prevention maintains mood stability, resulting in better fetal and maternal outcomes. However, despite the advantages, it also has some risks during pregnancy. Its use during the first trimester has notable oral cleft risks. Also, its metabolism is affected during pregnancy; thus, monitoring as well as dose adjustments are essential for maintaining therapeutic levels (Dolk et al., 2016). It is pregnancy category C, where mood stabilization and severe depressive episode prevention outweigh the risks.

Quetiapine is essential in the depressive and manic symptoms management of bipolar 1 disorder. It has a broad spectrum efficacy that favors its use by pregnant women for symptom control. It has a good reproductive safety profile and is thus used over other antipsychotics because of the lower risk of congenital malformations. It improves pregnancy outcomes and reduces maternal morbidity as a result of mood episode prevention. The risks include gestational diabetes as a result of metabolic side effects. Weight gain is also an issues that cause gestational hypertension as well as preeclampsia complications (Reutfors et al., 2020)Treating Pregnant Women With Bipolar 1 Disorder Discussion. When used close to delivery, there are risks of newborns withdrawal symptoms.

Clinical Practice Guidelines Exist for This Disorder and Use Them to Justify Your Recommendations

There are guidelines that are used in bipolar 1 disorder in pregnancy. They include the American Psychiatric Association (APA), the American College of Obstetricians and Gynecologists (ACOG) as well as the National Institute for Health and Care Excellence (NICE). They emphasize risk-benefit analysis, individualized treatment plans, and multidisciplinary collaboration to ensure better outcomes for the fetus and mother (MS & Kay Roussos–Ross, 2023). Both APA and ACOG guidelines provide recommendations for pregnant women with bipolar disorder management. They emphasize the importance of mood stabilization to mothers for relapse prevention. They advocate for risk-benefit analysis and effective and safe treatment. This guideline supports lamotrigine use because of its favorable safety profile during pregnancy (MS & Kay Roussos–Ross, 2023). They emphasize the need for stable moods that prevent manic episodes or severe depression that could have poor fetal and maternal outcomes. The low teratogenic risks and its effectiveness in depressive episode reduction make it the best option, thus aligning with the guidelines. For individualized care recognized by the guidelines, quetiapine can be used where the mood stabilizers are contraindicated or insufficient. Its reproductive safety profile supports its use in cases where the symptoms are not effectively controlled by other medications prescribed (MS & Kay Roussos–Ross, 2023)Treating Pregnant Women With Bipolar 1 Disorder Discussion.

The NICE guidelines advocate for medication avoidance because of teratogenic risks. NICE advocates for non-pharmacological interventions that are adjunct to pharmacotherapy. CBT is used in coping strategies development, relapse risk reduction, and emotional regulation improvement. Because it is non-invasive and has no medical-related risks, it is mostly the recommended non-pharmacological treatment aligning with NICE guidelines (Kendall et al., 2016).

Supporting Scholarly Resources

Kong et al. (2018) show that it is unclear whether fetuses of pregnant women exposed to lamotrigine have an increased risk of neurodevelopmental delay or deformity. They explain that the hazards of using lamotrigine during pregnancy and the possibility of uncontrollable maternal symptoms must be taken into consideration while managing pregnant women with bipolar disorder. Clinicians should review psychotropic medicines useful in treating bipolar pregnant women. Therefore, based on the available clinical data, lamotrigine has been shown to be the safest mood stabilizer to take during pregnancy. However, further research is required to determine the optimal course of treatment for bipolar illness in pregnant patients.

When faced with a crucial choice, women who need treatment should always talk to their doctor about the advantages and disadvantages of medication. If it is decided that treatment should continue while pregnant, the evidence-based material provided here should be helpful (Oruch et al., 2020)Treating Pregnant Women With Bipolar 1 Disorder Discussion. It is widely uncertain whether the use of antipsychotic medications causes teratogenesis. Oruch et al. (2020) show the general clinical guidelines that are acknowledged by physicians as well as prenatal carers for mothers and infants regarding antipsychotic users’ pregnancy and nursing. They include a thorough assessment of the risk/benefit ratio associated with medication exposure in fetuses and neonates. Second, the degree of mental disease in the mother. Finally, choose the right agent carefully, making sure it has a good safety/efficacy profile. Antipsychotic drug exposure during the third trimester of pregnancy increases the risk of extrapyramidal neurological abnormalities, withdrawal symptoms, preterm, low or high birth weight in the neonate, as well as gestational diabetes in the pregnant woman (Oruch et al., 2020). Therefore, when receiving quetiapine therapy, female patients who are of reproductive age must inform their doctor when they are pregnant or want to get pregnant.

CBT should be incorporated in caring for pregnant women with bipolar 1 disorder because of because it exempts the side effects that results from medications. The authors show that the medication are very essential in bipolar management but have some draw backs. During pregnancy, CBT, an evidence based practice help avoid the adverse effects of the medications (Cuthrell et al., 2022)Treating Pregnant Women With Bipolar 1 Disorder Discussion. Medications should be used if the benefits outweigh the risks. Therefore, there is research gap on whether to stop antipsychotic drugs during pregnancy, to provide drug that have no potential side effect to the mother and fetus development. There should be a balance to ensure antipsychotic drugs side effects are not underlooked and benefits overlooked.

References

Cuthrell, K. M., Singh, M., Villamar, M., & Shabbir, U. (2022). Antipsychotic Medications and Cognitive Behavior Therapy in Pregnant Women with Bipolar Disorder. Asian Journal of Biochemistry, Genetics and Molecular Biology, 12(4), 42-59. http://research.manuscritpub.com/id/eprint/1295

Dolk, H., Wang, H., Loane, M., Morris, J., Garne, E., Addor, M. C., … & de Jong-van den Berg, L. T. (2016). Lamotrigine use in pregnancy and risk of orofacial cleft and other congenital anomalies. Neurology, 86(18), 1716-1725. https://doi.org/10.1212/WNL.0000000000002540

Kendall, T., Morriss, R., Mayo-Wilson, E., Meyer, T. D., Jones, S. H., Oud, M., & Baker, M. R. (2016). NICE guidance on psychological treatments for bipolar disorder. The Lancet Psychiatry, 3(4), 317-320. https://doi.org/10.1016/S2215-0366(16)00082-1 Treating Pregnant Women With Bipolar 1 Disorder Discussion

Kong, L., Zhou, T., Wang, B., Gao, Z., & Wang, C. (2018). The risks associated with the use of lamotrigine during pregnancy. International Journal of Psychiatry in Clinical Practice, 22(1), 2-5. https://doi.org/10.1080/13651501.2017.1341986

MS, M., & Kay Roussos–Ross, M. D. (2023). Treatment and Management of Mental Health Conditions During Pregnancy and Postpartum. DOI: 10.1097/AOG.0000000000005202

ORDER TODAY

Oruch, R., Pryme, I., Fasmer, O., & Lund, A. (2020). Quetiapine: An objective evaluation of pharmacology, clinical uses and intoxication. EC Pharmacol Toxicol, 8(4), 1-26.

Özdel, K., Ayşegül, K. A. R. T., & Türkçapar, M. H. (2021). Cognitive behavioral therapy in treatment of bipolar disorder. Archives of Neuropsychiatry, 58(Suppl 1), S66. https://doi.org/10.29399%2Fnpa.27419

Reutfors, J., Cesta, C. E., Cohen, J. M., Bateman, B. T., Brauer, R., Einarsdóttir, K., … & Bröms, G. (2020). Antipsychotic drug use in pregnancy: a multinational study from ten countries. Schizophrenia research, 220, 106-115 Treating Pregnant Women With Bipolar 1 Disorder Discussion